“Triple Threat-Triple Benefit: The Rise of GLP1-GCG-FGF21 Tritagonists in Tomorrow’s Metabolic Medicine ”. Diabzen 3, no. 3 (December 1, 2025): 43–48. Accessed February 27, 2026. https://www.thediabzen.com/index.php/d/article/view/19.